
Covid-19 ã¯ã¯ãã³ããšã€ãºçºçã®åå ãšãªã£ãŠããããšããè±å¯ãªç§åŠç蚌æ ãšæ¿åºããŒã¿ã«ãã£ãŠæããã«ãªã£ãã
AIDSïŒåŸå€©æ§å ç«äžå šçå矀ïŒãšã¯ãå ç«ç³»ãèããæãªãããå Žåã«èµ·ãããçåœãè ããå¯èœæ§ã®ããå€ãã®ææçãç æ°ã衚ãåç§°ãšããŠäœ¿ãããŠãããã®ã§ãã
åŸå€©æ§å ç«äžå šçåçŸ€ã®æ¹ã¯ãç¹å®ã®ãããçºçãããªã¹ã¯ããéåžžã¯å ç«åã®äœã人ã«ããèµ·ãããªããããªææçã«ããããªã¹ã¯ãé«ããªããŸãã
ããã§ã¯ãã³ããã-19ã¯ã¯ãã³ãã被æ¥çš®è
ã«åŸå€©æ§å
ç«äžå
šçå矀ïŒAIDSïŒãŸãã¯ã³ããã-19ã¯ã¯ãã³èªçºåŸå€©æ§å
ç«äžå
šçå矀ïŒVAIDSïŒãšãã衚çŸã§ããªãé¡äŒŒã®å±æ§ãæã€æ°ããç¶æ
ãçºçãããŠãããšããäžé£ã®åŒ·ã蚌æ ã玹ä»ããŸãã
ç©ç蚌æ ïŒA
ã¯ã¯ãã³ã®å¹æã¯è¡°ããªãããå
ç«ã·ã¹ãã ã®æ§èœã¯è¡°ãã
ã¯ã¯ãã³ã®å¹æãšã¯ãã¯ã¯ãã³ãæ¥çš®ãã人ã®å ç«ã·ã¹ãã ã®æ§èœãšãæ¥çš®ããŠããªã人ã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒãããã®ã§ãå®éã«ã¯ã¯ã¯ãã³ã®å¹æã§ã¯ãããŸããã
äœãåããŠçްèã«ééãããšããææãä¹ãè¶ããããã«å¿ èŠãªãã¹ãŠã®çްèãšéãéå ·ãäœãã䜿çšããã®ã«æ°æ¥ãããããšããããŸããææåŸãå ç«ã·ã¹ãã ã¯ããã®ç æ°ããäœãå®ãæ¹æ³ã«ã€ããŠåŠãã ããšãèšæ¶ããŸãã
ã¯ã¯ãã³ã¯ãææçãæš¡å£ããããšã§å ç«ã®çºéãå©ãããšèšãããŠããŸããã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ããããæš¡å£ææããªããªããšãäœã«ã¯ãèšæ¶ãT现èãšæäœã®äŸçµŠãæ®ãããå°æ¥ãã®ç æ°ãšã©ã®ããã«æŠãããèšæ¶ããããã«ãªãã®ã§ã
ã€ãŸããåœå±ããã¯ã¯ãã³ã®å¹æã¯æéãšãšãã«åŒ±ãŸãããšè¿°ã¹ãŠããã®ã¯ãæ¬åœã®æå³ã¯ããå
ç«ã·ã¹ãã ã®æ§èœãæéãšãšãã«åŒ±ãŸãããšããããšãªã®ã§ãã
Covid-19泚å°ã«é¢ããŠãŒ
ã¯ã¯ãã³ã®æå¹æ§ãïŒ50ïŒ ã§ããã°ãã¯ã¯ãã³ãå®å šã«æ¥çš®ãã人ã¯ãæ¥çš®ããŠããªãäººã«æ¯ã¹ãŠCovid-19ã«å¯ŸããŠ50ïŒ ä»¥äžä¿è·ãããŠããããšã«ãªããèšãæããã°ãå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã¯ãCovid-19ã«å¯Ÿæããå ç«ç³»ã50ïŒ åäžããŠããããšã«ãªãã
ã¯ã¯ãã³ã®æå¹æ§ã0ïŒ ã§ããã°ãã¯ã¯ãã³ãæ¥çš®ããäººã¯æ¥çš®ããŠããªãäººãšæ¯ã¹ãŠCovid-19ããå®ãããªãããšã«ãªããã¯ã¯ãã³ã¯ç¡å¹ã§ããããšãæå³ããŸããèšãæããã°ãå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã¯ãã¯ã¯ãã³æªæ¥çš®ã®äººãšåçã®å ç«ã·ã¹ãã ãæã¡ãCovid-19ã«å¯ŸåŠããŠããããšã«ãªãã
ããããã¯ã¯ãã³ã®æå¹æ§ã-50ïŒ ã§ããã°ãã¯ã¯ãã³æªæ¥çš®è ã¯å®å šæ¥çš®è ããã50ïŒ Covid-19ããä¿è·ãããŠããããšã«ãªããèšãæããã°ãã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ã®æ§èœã¯ãã¯ã¯ãã³æªæ¥çš®è ã®èªç¶å ç«ç³»ã®æ§èœãã50ïŒ æªããšããããšã§ããããããã£ãŠãCovid-19ã¯ã¯ãã³ã¯å ç«ç³»ãæå·ããŠããã
ç©ç蚌æ ïŒB
è±åœã®ããŒã¿ã§ã¯ãCovid-19 ã¯ã¯ãã³ã¯çŸå®çã«åŠå®çãªå¹æãæã£ãŠããŸãã
è±åœå¥åº·å®å
šå±ïŒUKHSAïŒã¯ãæ¯é±ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžãçºè¡ããŠãããåå ±åæžã«ã¯ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19çäŸãå
¥é¢ãæ»äº¡ã«é¢ãã4é±éåã®ããŒã¿ãå«ãŸããŠããŸãã
以äžã¯ãUKHSA Vaccine Surveillance Report - Week 5 - 2022ããåŒçšãããã€ã³ã°ã©ã³ãã®18æ³ä»¥äžã®å幎霢局ã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19æ£è
çããã³ã€ã³ã°ã©ã³ãã®å
šæäººã®10äžäººåœããã®å¹³åæ£è
æ°ã§ãã
10äžäººåœããã®çäŸæ°ã¯ããã¹ãŠã®å¹Žéœ¢å±€ã§æªæ¥çš®è
ãæãå°ãªãã3åæ¥çš®è
ã®çäŸæ°ã¯ã»ãšãã©ã®å¹Žéœ¢å±€ã§æªæ¥çš®è
ã®çŽ2åã2åæ¥çš®è
ã®çäŸæ°ã¯ã»ãšãã©ã®å¹Žéœ¢å±€ã§æªæ¥çš®è
ã®çŽ3åãšãªã£ãŠããããšããããã
ãã®ããŒã¿ã ãã§ã¯ãæãç±å¿ãªã¯ã¯ãã³æè·è ã§ãããæ·±ãææ ®ãã¹ããã®ã§ããã
ããŠãçäŸçãããã£ããšããã§ããã¡ã€ã¶ãŒã¯ã¯ãã³å¹æèšç®åŒã䜿ã£ãŠãå®éã®ã¯ã¯ãã³å¹æãèšç®ããŠã¿ãããšã«ãããã
ã¯ã¯ãã³æªæ¥çš®äŸç-ã¯ã¯ãã³æ¥çš®äŸçïŒã¯ã¯ãã³æªæ¥çš®äŸçïŒã¯ã¯ãã³æå¹æ§
äŸïŒ18æ³ä»¥äž80æ³æªæºã®äºéã¯ã¯ãã³æ¥çš®è
ïŒ1,846.38 - 5,226.1 / 1,846.38 = ãã€ãã¹183%ã
ãããã£ãŠã2022幎1æã®ã€ã³ã°ã©ã³ãã«ãããæäººå šäœã«å¯Ÿããå®éã®Covid-19ã¯ã¯ãã³å¹æã®å¹³åå€ã¯ãMINUS-183%ã§ãã£ãã
以äžã¯ãåäºéæ¥çš®å¹Žéœ¢å±€ã§Covid-19ã¯ã¯ãã³ã®æå¹æ§ã蚌æããããã®ã§ããŒ
Covid-19ã®ã¯ã¯ãã³å¹æãæãäœãã£ãã®ã¯ã2022幎1æãéããŠã€ã³ã°ã©ã³ãã®40-49æ³ã®å¹Žéœ¢å±€ã§ããã€ãã¹209.4%ãèšé²ãã50-59æ³ã®å¹Žéœ¢å±€ãããã«é ãåã°ãªãçµæãšãªããŸããã
ããããå¿ããŠã¯ãªããªãã®ã¯ãå¥çŽAã§ç޹ä»ãã蚌æ ã§èšŒæããããã«ãã¯ã¯ãã³å¹æã¯å®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãšã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒããææšã§ãããšããããšã§ãã
ãããã£ãŠãUKHSAã®ããŒã¿ã¯ãCovid-19ã®æ³šå°ãèªç¶å
ç«ç³»ãç Žå£ããŠããããšã瀺ããŠããã®ã§ãã
ç©ç蚌æ ïŒC
è±åœã®ããŒã¿ã§ã¯ãå®å
šãªã¯ã¯ãã³æ¥çš®ãåãã人ã¯ãå
ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ãäœäžããŠããã
å ç«ç³»ã®ããã©ãŒãã³ã¹ãèšç®ããããã«ã¯ãã¯ã¯ãã³ã®å¹æãèšç®ããæ¹æ³ãå°ãå€ããå¥çŽBã«èšèŒãããŠããçäŸæ°ã«åºã¥ããŠãã¯ã¯ãã³æ¥çš®è ãšéæ¥çš®è ã®æå€§çäŸæ°ã§çããå²ãå¿ èŠããããŸãã
æªæ¥çš®äŸç - ã¯ã¯ãã³æ¥çš®äŸç / æå€§æªæ¥çš®äŸç / ã¯ã¯ãã³æ¥çš®äŸç = å ç«ç³»ããã©ãŒãã³ã¹ äŸïŒ18-80æ³ã®äºéã¯ã¯ãã³æ¥çš®è ïŒ 1,846.38 - 5,226.1 / 5,226.1 = ãã€ãã¹65% ãšãªãã
次ã®ã°ã©ãã¯ã2022幎1æã«ããã«ã¯ã¯ãã³æ¥çš®è
ã®å
ç«ã·ã¹ãã ã«çããçã®è¢«å®³ã®å€§ããã幎霢局å¥ã«ç€ºãããã®ã§ãããŒ
ã€ãŸããã€ã®ãªã¹ã®å¹³åçãª2åæ¥çš®è
ã¯ããŠã€ã«ã¹ã现èããããšéãããã®å
ç«ã·ã¹ãã ãæåŸã®35%ãŸã§äœäžããŠãããšããããšã§ãããããããã®ããŒã¿ã¯åãªãäžéæ§ã®ãã®ãªã®ã ãããããããšããå®å
šãªã¯ã¯ãã³æ¥çš®ãåãã人ã
ã®å
ç«ã·ã¹ãã ã®æ§èœã¯ãé±ããšã«äœäžããŠããã®ã ãããã
ç©ç蚌æ ïŒD
è±åœã®ããŒã¿ã§ã¯ãå®å
šæ¥çš®éå£ã®å
ç«ç³»ã®ããã©ãŒãã³ã¹ã¯é±ããšã«äœäžããŠããããšã蚌æãããŠãã
UKHSAã®éå»ã®ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã«èšèŒãããŠããçäŸæ°ãåèã«ããã°ãé廿°ã¶æéã®çŸå®ã®ã¯ã¯ãã³å¹æã被æ¥çš®è ã®å ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ã远跡ããããšãã§ããŸãã
ããã§ã以äžã®ã¬ããŒãã«èšèŒãããŠããçäŸæ°ãåèã«ãããŒ
Covid-19 Vaccine Surveillance Report â Week 37â² (Published by PHE)
âCovid-19 Vaccine Surveillance Report â Week 41â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 45â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 49â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 1 â 2022â (Published by UKHSA)
ãããŠã2021幎8æ16æ¥ãã2022幎1æ2æ¥ãŸã§ã®çŸå®ã®Covid-19ã¯ã¯ãã³ã®æå¹æ§ãèšç®ããŸãã ãŒ
2021幎ã®37é±ç®ã«æåã®ããŒã¹ã¿ãŒã·ã§ãããè¡ãããŸãããããã®ã°ã©ãã¯ããã®åŸã®2ã«æéã§ããã«ã¯ã¯ãã³å¹æãé«ãŸã£ãããæç¢ºã«ç€ºããŠããŸããããããæ®å¿µãªããããã®ããŒã¹ããããã«çåœã§ãã£ããã瀺ããŠãããCovid-19ã¯ã¯ãã³ã®æå¹æ§ã¯49é±ãã52é±ã®éã«æãããã¬ãã«ãŸã§äœäžããŠããŸãã
次ã®ã°ã©ãã¯ã21幎8æ16æ¥ãã22幎1æ2æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããå
šå¹Žéœ¢å±€ã®å
šäœçãªå
ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ã瀺ããŠããŸããŒ
äžèšãããããããã«ã40-49æ³ã¯22幎1æ2æ¥ãŸã§ã«ãã€ãã¹60%ãèšé²ããå
ç«ç³»ã®ããã©ãŒãã³ã¹ãæãæªãã£ããå³è¡šCã§ã¯ã40-49æ³ã®å
ç«ç³»ã®ããã©ãŒãã³ã¹ã¯ã22幎1æ30æ¥ãŸã§ã«ãã€ãã¹67.7%ã«äœäžããŠããããšããããããã®ããšãããCovid-19ã®ã¯ã¯ãã³ã¯èªç¶å
ç«ç³»ã«ãã¡ãŒãžãäžããé±ã远ãããšã«æªåããŠããããšããããã
ç©ç蚌æ ïŒE
è±åœã®ããŒã¿ã§ã¯ãå®å
šãªã¯ã¯ãã³æ¥çš®è
ãCovid-19ã§æ»äº¡ãã確çãé«ããªã£ãã
以äžã®å³ã¯ã第5é±UKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒãã§çºèŠãããæ»äº¡æ°ãšããã«ã¯ã¯ãã³æ¥çš®è
ã®èŠæš¡ããç®åºãããã€ã³ã°ã©ã³ãã®18æ³ä»¥äžã®å幎霢局ã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19æ»äº¡çã§ãã ãŒ
ããã«ã¯ã¯ãã³æ¥çš®è
ã¯ã18-29æ³ãš40-49æ³ãé€ããã¹ãŠã®å¹Žéœ¢å±€ã§ã10äžäººåœããã®æ»äº¡çãæãé«ããªã£ãŠãããããããä»åŸæ°é±éã§ããã®æ»äº¡çã¯ãå³è¡šDã«åºã¥ã2ã€ã®ç°åžžå€ã®éã§å
¥ãæ¿ãããé±ããšã«ã¯ã¯ãã³æ¥çš®è
ã®ç¶æ³ãæªåããŠããããšãäºæ³ãããã
ç©ç蚌æ ïŒF
è±åœã®ããŒã¿ã§ã¯ãCovid-19ã¯ã¯ãã³ã¯æ»ã«å¯ŸããçŸå®çãªè² ã®å¹æãæã€
æ»äº¡çãããã£ãã®ã§ãåã³ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æèšç®åŒã䜿ã£ãŠãæ»äº¡ã«å¯ŸããçŸå®ã®ã¯ã¯ãã³å¹æãèšç®ããããšãã§ããã
22幎1æ3æ¥ãã1æ30æ¥ã®éã«ã€ã³ã°ã©ã³ãã§å®éã«è¡ãããCovid-19ã¯ã¯ãã³ã®æ»äº¡ã«å¯Ÿãã广ã¯ã80æ³ä»¥äžã§-110.24%ã70-79æ³ã§-97%ã18æ³ä»¥äžã®ãã¹ãŠã®æäººã®å¹³åã§-98.14%ãšäœããã®ã§ãã£ãã
ããããå¿ããŠã¯ãªããªãã®ã¯ãå¥çŽAã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è
ã®å
ç«ç³»ã®æ§èœãšã¯ã¯ãã³æªæ¥çš®ã®äººã®å
ç«ç³»ã®æ§èœãšãæ¯èŒããææšã§ãããšããããšã§ããã
ç©ç蚌æ ïŒG
è±åœã®ããŒã¿ã§ã¯ãé«éœ¢è
ã®äžéšã¯ãã§ã«VAIDSãçºçããŠããå¯èœæ§ããããŸãã
以äžã®ã°ã©ãã¯ãUKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒã第5é±ïŒ2022幎ïŒã®10äžäººåœããã®æ»äº¡çïŒCovid-19ïŒã«åºã¥ããå®å
šæ¥çš®éå£ã®æ»äº¡ã«å¯Ÿããå
ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ã瀺ãããã®ã§ã ïŒ
Covid-19ã®ã¯ã¯ãã³ã«ãã£ãŠå ç«ç³»ããã¡ãŒãžãåããé±ã远ãããšã«æªåããŠããããšã瀺ãéå»ã®åŸåãšåæ§ã«ãå ç«ç³»ã®ããã©ãŒãã³ã¹ãæãäœãã®ã¯ãæåã«ã¯ã¯ãã³ãæ¥çš®ãã人ãã¡ã§ã80代以äžã-52.4%ããããŠ70ïœ79æ³ã-49.2%ãèšé²ããŠããããšããããã
ãããããã®ããŒã¿ã«ã¯æ°ã«ãªãç°åžžãããã30-39æ³ã®å¹Žéœ¢å±€ã§ã¯ãå ç«ç³»ã®ããã©ãŒãã³ã¹ã29%çšåºŠãšãã©ã¹ã«ãªããšäºæ³ãããããããã§ã¯ãªããçŸåšã-15.4%ã§ãããããã«ã¯ããã€ãã®çç±ãèããããããã©ããè¯ããšã¯èšããªãã
30-39æ³ãæ¬åœã«æªãã®ãããããã¯ä»ã®å¹Žéœ¢å±€ãç§ãã¡ãèšãããŠããããããã£ãšæªãã®ãã
ãããã«ãããCovid-19ã®æ³šå°ã«ãã£ãŠãé«éœ¢è ã匱è ãå ç«æ©èœã倱ããCovid-19ã§æ»äº¡ãã確çãã¯ã¯ãã³æªæ¥çš®ã®äººãããé«ããªã£ãããšããããŒã¿ã確å®ã«äŒããŠããããšã¯ç¢ºãã§ãããã
ç©ç蚌æ ïŒH
ã¹ã³ããã©ã³ãå
¬è¡è¡çå±ã®ããŒã¿ã«ãããšãå®å
šãªã¯ã¯ãã³æ¥çš®ãåãã人ãCovid-19ã§æ»äº¡ãã確çãé«ããªã£ãã
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã¯ãæ¯é±ãã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19æ£è ãå ¥é¢ãæ»äº¡ã«é¢ããããŒã¿ãå«ãCovid-19çµ±èšå ±åæžãçºè¡šããŠããŸãã
以äžã®ã°ã©ãã¯ã2æ2æ¥ïŒæ°ŽïŒã«çºè¡šãããå ±åæžã«ãããšã21幎12æ25æ¥ãã22幎1æ21æ¥ãŸã§ã®ã¹ã³ããã©ã³ãã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19ã«ããæ»äº¡ã®å²åã瀺ããŠãããŒ
次ã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®å¹Žéœ¢æšæºåãã10äžäººåœããã®Covid-19æ»äº¡çã瀺ããŠããŸãããã®ããŒã¿ã¯ã22幎2æ2æ¥ïŒæ°ŽïŒã«çºè¡šãããPHS Covid-19çµ±èšå ±åæžã®54ããŒãžã«ãã衚16ããæœåºããããã®ã§ããã
1æ21æ¥ã«çµããçŽè¿ã®é±ã§ã¯ãå®å šæ¥çš®è ã¯éæ¥çš®è ã«æ¯ã¹ãŠçµ±èšçã«2å以äžãCovid-19ã§æ»äº¡ãã確çãé«ãã£ãã
éå»1ãµæã§ã¯ã¯ãã³æ¥çš®è
ã®æ»äº¡çãæãé«ãã£ãã®ã¯ã1æ15æ¥ã«å§ãŸãé±ã§10äžäººããã15.49人ã§ãã£ãããã¯ã¯ãã³æªæ¥çš®è
ã®æ»äº¡çãæãé«ãã£ãã®ã¯ã1æ8æ¥ã«å§ãŸãé±ã§10äžäººããã10.93人ã§ãã£ãã
ç©ç蚌æ ïŒI
ã¹ã³ããã©ã³ãå
¬è¡è¡çå±ã®ããŒã¿ã§ã¯ãCovid-19ã¯ã¯ãã³ã¯æ»äº¡ã«å¯ŸããŠçŸå®çã«åŠå®çãªå¹æãæã£ãŠããã
以äžã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãå
¬è¡è¡çå±ããæäŸãããæ°å€ã«ãããéå»4é±éã®æ»äº¡ã«å¯Ÿããå®éã®ã¯ã¯ãã³å¹æã瀺ããŠããŸããŒ
æ»äº¡ã«å¯Ÿããã¯ã¯ãã³ã®å¹æã¯ãå°ãªããšã12æ25æ¥ä»¥éãã€ãã¹ãšãªã£ãŠããã22幎1æ21æ¥çŸåšããã€ãã¹112ïŒ ãšããé©ç°çãªæ°åã«èœã¡èŸŒãã§ããã
ããããç©ç蚌æ Aã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ã¯ã¯ãã³ãè©äŸ¡ãããã®ã§ã¯ãªããã¯ã¯ãã³æ¥çš®è
ã®å
ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ããã¯ã¯ãã³æªæ¥çš®ã®äººã®å
ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ãšæ¯èŒããŠè©äŸ¡ãããã®ã§ããããšãå¿ããŠã¯ãªããªãã
ç©ç蚌æ ïŒJ
ã¹ã³ããã©ã³ãå
¬è¡è¡çå±ã®ããŒã¿ã«ãããšãå®å
šæ¥çš®è
ã®äžã«ã¯ããã§ã«VAIDSãçºçããŠããå¯èœæ§ãããã
以äžã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãå
¬è¡è¡çå±ã®çºè¡šã«ãããšã1æ15æ¥ãã22幎1æ21æ¥ã®éã«æ»äº¡ãããã¹ãŠã®æäººã¯ã¯ãã³æ¥çš®è
ã®å¹³åçãªå
ç«ã·ã¹ãã ã®æ§èœã瀺ããŠããŸããŒ
å šæäººã®æ»äº¡ã«å¯Ÿããå ç«ã·ã¹ãã ã®å¹³åçãªããã©ãŒãã³ã¹ã¯ãã¹ã³ããã©ã³ãã§ã¯-53%ã«çžåœããå¥çŽGã«ç€ºããã€ã³ã°ã©ã³ãã®å¹³å-50%ããè¥å¹²é«ãã
ã€ãŸããCovid-19ã®æ³šå°ã¯å¹æããªãã ãã§ãªããå
ç«ç³»ã«ãã¡ãŒãžãäžããæ¥çš®è
ãåŸå€©æ§å
ç«äžå
šçå矀ãçºçããã¯ã¯ãã³æªæ¥çš®è
ãããæ»äº¡ãã確çãã¯ããã«é«ãããšããããŒã¿ã¯ç¢ºå®ã«äŒããŠããã®ã§ããã
ç©ç蚌æ ïŒK
ã«ããæ¿åºã®ããŒã¿ã§ã¯ãCovid-19 ã¯ã¯ãã³ãå
ç«ã·ã¹ãã ãç Žå£ããŠããããšã確èªãããŠããã
次ã®å³ã¯ãã«ããæ¿åºCovid-19 Daily Epidemiological Updatesã®1æ15æ¥ã®æ°åãã12æ4æ¥ã®æ°åãåçŽã«å·®ãåŒããšã21幎12æ5æ¥ãã22幎1æ15æ¥ãŸã§ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®æ£è
æ°ã§ãããŒ
ã«ããã§ã¯ã12æ4æ¥ã®å ±åã«ãããšãå°ãªããšã2åæ¥çš®ããŠãã人ã2220äžäººãå°ãªããšãäžéšæ¥çš®ããŠãã人ã2320äžäººãšãªã£ãŠããŸããå ¬åŒçµ±èšã«ãããšã2020幎ã®ã«ããã®äººå£ã¯3,801äžäººãšæšå®ãããŠããŸãã
ãããã£ãŠãã«ããã§ã¯2310äžäººãå°ãªããšã1åã®Covid-19ã¯ã¯ãã³ãæ¥çš®ããŠãããããã«ããã§Covid-19ã¯ã¯ãã³ãæ¥çš®ããŠããªã人ã¯çŽ1481äžäººãšãªãã
次ã®ã°ã©ãã¯ãäžèšã®äººå£èŠæš¡ãšçäŸæ°ã«åºã¥ããŠãã«ããã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19çäŸçã瀺ããŠããŸãã
以äžã®ã°ã©ãã¯ãäžèšã®çäŸæ°ã«åºã¥ããŠã21幎12æ5æ¥ãã22幎1æ15æ¥ãŸã§ã®éã«ã«ããã§å®éã«è¡ãããCovid-19ã¯ã¯ãã³ã®å¹æã瀺ããŠããŸãã
ããããç©ç蚌æ ïŒAã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ã®ããã©ãŒãã³ã¹ãšã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ç³»ã®ããã©ãŒãã³ã¹ãšãæ¯èŒããææšã§ããããšãå¿ããŠã¯ãªããªãã
次ã®ã°ã©ãã¯ã21幎12æ5æ¥ãã22幎1æ15æ¥ãŸã§ã®ã«ããã«ãããå®å
šæ¥çš®è
ã®å
ç«ç³»ã®ããã©ãŒãã³ã¹ã瀺ããŠãããŒ
å®å
šã«äºé²æ¥çš®ãåããã«ãã人ã®å¹³åçãªå
ç«åã¯ãããçš®ã®ãŠã€ã«ã¹ãç¹å®ã®çãªã©ãšéãããã®å
ç«ã·ã¹ãã ã®æåŸã®18.45%ã«ãŸã§äœäžããŠããã®ã§ãããããã¯ã¯ãã³æ¥çš®ãã«ããåœæ°ã«ããããããã®ã§ãã
ç©ç蚌æ ïŒL
å®å
šãªã¯ã¯ãã³æ¥çš®ãåããè
ã¯ãNæäœãäœãããšãã§ããªã
è±åœå¥åº·å®å
šå±ã¯ããã®ã¯ã¯ãã³ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã ãã§ãªãããŠã€ã«ã¹ã®ä»ã®éšåã«å¯Ÿããæäœãç£çããææåŸã®äœã®çåŸçèœåã劚害ããããšãæããã«ãããå
·äœçã«ã¯ãã¯ã¯ãã³æªæ¥çš®è
ã§ã¯åå¿ã«éèŠãªåœ¹å²ãæãããŠã€ã«ã¹ã®æ®»ã§ãããã¯ã¬ãªã«ãã·ãã¿ã³ãã¯è³ªã«å¯Ÿããæäœãäœãããªããããªã®ã ã
ç©ç蚌æ ïŒM
Covid-19ã¯ã¯ãã³ãèªç¶å
ç«ç³»ãæå¶ããããšãçºèŠããç§åŠçç ç©¶
ãSARS-CoV-2 mRNAã¯ã¯ãã³ã«ããèªç¶å
ç«æå¶ããšé¡ãããç ç©¶ã§ããThe role of G-quadruplexes, exosomes and microRNAs' 21 Jan 22ã«çºè¡šãããmRNA Covid-19ã¯ã¯ãã³ã«ãã£ãŠããããããéºäŒåæ¹å€ã人éã®å¥åº·ã«å€æ§ãªåœ±é¿ãäžãããšãã蚌æ ã®æ°ã
ãæç€ºããŠããŸãã
ç¥çµå€æ§çŸæ£ãšã®çŽæ¥çãªå æé¢ä¿ãããå¯èœæ§ãããããšã
å¿çç
å ç«æ§è¡å°æ¿æžå°ç
ãã«éº»çº
èçŸæ£
é©å¿å ç«ã®äœäž
è «çã®ç£çãŸãã¯åœ¢æã®å¢å ã
ããã³DNAæå·
æ¬èª¿æ»ã®è©³çްãªå
èš³ã¯ãã¡ãã§ã芧ããã ããŸãã
ç©ç蚌æ ïŒN
Covid-19ã¯ã¯ãã³ãšé¢é£ããçã®çºççãéåžžã«é«ããšããç§åŠç調æ»çµæ
å¥çŽLã®ç ç©¶ããåŒçšãã以äžã®è¡šã¯ã1990幎ãã2021幎12æ12æ¥ãŸã§ã®VAERSããŒã¿ããŒã¹ã«ãããŠãCovid-19ã¯ã¯ãã³ã«é¢é£ããŠããããã¯ä»ã®ãã¹ãŠã®å©çšå¯èœãªã¯ã¯ãã³ã«é¢é£ããŠãããã瀺ãããã€ãã®çšèªãçºçããã€ãã³ãã®æ°ãšãäºã€ã®æ°ã®éã®æ¯çã瀺ãããã®ã§ããã
COVID-19ã¯ã¯ãã³æ¥çš®åŸã®ä¹³ããã®å ±åæ°ã¯3åãB现èãªã³ãè «ã®å ±åæ°ã¯6å以äžã§ãã£ããæ¿Ÿèæ§ãªã³ãè «ã¯1äŸãé€ãããã¹ãŠCOVID-19ã¯ã¯ãã³ãšé¢é£ããŠããã
èµèããã¯3å以äžã§ãã£ããäžã®è¡šãç·åãããšãVAERSãžã®ããå ±åã¯ãä»ã®ãã¹ãŠã®ã¯ã¯ãã³ã«é¢ãããã®ã«æ¯ã¹ãŠãCOVID-19ã¯ã¯ãã³æ¥çš®ã«é¢é£ãããã®ã2åå€ãããšãããããŸãããã®ããšã¯ãèè ãã®æèŠã§ã¯ãç·æ¥ã«èª¿æ»ããå¿ èŠãããã·ã°ãã«ãæ§æããŠããã
ããã¯ãéå»1幎éã«mRNAã¯ã¯ãã³ã®æ¥çš®ãåããäººã®æ°ããä»ã®ãã¹ãŠã®ã¯ã¯ãã³æ¥çš®ãšæ¯èŒããŠäžé£ãåãã§ãããšããèšåã§ã¯èª¬æã§ããªãã
CDCã®ããŒã¿ã«ãããšã2008幎ãã2020幎ã®éã«ãç±³åœã§ã¯17å2,000äžå以äžã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ãããããšãåãã£ãŠããããã§ããäžæ¹ãCovid-19ã®æ¥çš®ãã£ã³ããŒã³ãå§ãŸã£ãŠãã22幎1æ28æ¥ãŸã§ã«ãç±³åœã§ã¯åèš5å4990äžååã®Covid-19ã¯ã¯ãã³ãæäžãããŸããã
ã¯ã¯ãã³æ¥çš®ãšé¢é£ãããã®çã®çºççã®å¢å ã®çç±ã¯ãç§ãã¡ãããã€ãã®å³è¡šã§èšŒæããããã«ãCovid-19ã¯ã¯ãã³ãèªç¶å ç«ã·ã¹ãã ãç Žå£ããŠããããã§ããå¯èœæ§ãé«ããããããããšã«ãã£ãŠãå ç«ç³»ã¯çãåŒãèµ·ããå¯èœæ§ã®ããä»ã®ææçãšæŠãããšãã§ããªããªãã®ã§ãã
äŸãã°ãHPVïŒããããããŒããŠã€ã«ã¹ïŒææã¯ãç¹å®ã®é é žéšãããèéãããåå®®é žããããã®ä»å€ãã®çš®é¡ã®ããã«é¢é£ããŠããŸãããŸãããªã³ãè «ããŠã€ã«ã¹ææãšã®é¢é£ãææãããŠããŸãã
ãšã€ãºã«é¢é£ããããã®äžèЧã¯ãã¡ãã§ã芧ããã ããŸãã
Closing Arguments
ã€ã³ã°ã©ã³ããã¹ã³ããã©ã³ããã«ããã®æ¿åºå ¬åŒããŒã¿ã¯ãCovid-19ã®æ³šå°ãçŸå®çã«ã¯ãã€ãã¹å¹æã§ããããšã蚌æããŠããŸãã
ããããã¯ã¯ãã³ã®æå¹æ§ã¯å®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãšæ¯èŒããææšãªã®ã§ãã
ã€ãŸããã¯ã¯ãã³ãæ¥çš®ãã人ã®å ç«ã·ã¹ãã ã¯ãæ¥çš®ããŠããªã人ã®èªç¶å ç«ã·ã¹ãã ããå®ã¯å£ã£ãŠããã®ã§ãã
ããããç§ãã¡ãæç¢ºã«ç€ºããããã«ããã®å ç«ç³»ã®å£åã¯é±ããšã«æªåããŠãããçŸåšãã€ã³ã°ã©ã³ããšã¹ã³ããã©ã³ãã®é«éœ¢è ã匱è ã®éã§ãæ»ã«å¯Ÿããå ç«ç³»ã®æ§èœããã€ãã¹ã«ãªãå§ããŠããã
æè¿ã®ç§åŠçç ç©¶ã«ãããšãCovid-19ã¯ã¯ãã³ã¯èªç¶å ç«ç³»ãæå¶ããã¯ã¯ãã³ã«ãã£ãŠããããããéºäŒåçµã¿æãããå ç«æ§è¡å°æ¿æžå°çãå¿ççãªã©äººéã®å¥åº·ã«ããŸããŸãªåœ±é¿ãåãŒãããšã倿ããŠããŸãããããã¯ããããèªå·±å ç«çŸæ£ã§ããã
ãŸããåãç ç©¶ã§ãè «çã®çºçã圢æãå¢å ããŠããããšãããã£ããããã¯ãçã®åå ãšãªãç¹å®ã®ãŠã€ã«ã¹ã«å¯Ÿæã§ããªãå ç«ã·ã¹ãã ã®æå¶ãšé¢ä¿ãããã
AIDSïŒåŸå€©æ§å ç«äžå šçå矀ïŒãšã¯ãå ç«ç³»ãæ·±å»ãªãã¡ãŒãžãåãããšãã«èµ·ãããçåœãè ããå¯èœæ§ã®ããå€ãã®ææçãç æ°ãæãåç§°ã§ãã
åŸå€©æ§å ç«äžå šçåçŸ€ã®æ¹ã¯ãç¹å®ã®ããããéåžžã¯å ç«åã®äœã人ã«ããèµ·ãããªããããªææçãçºçãããªã¹ã¯ãé«ããªããŸãã
ãããã£ãŠãç§ãã¡ã¯Covid-19泚å°ãåŸå€©æ§å ç«äžå šçå矀ããããã¯Covid-19ã¯ã¯ãã³èªçºåŸå€©æ§å ç«äžå šçå矀ïŒVAIDSïŒãšããèšãããã®ãªããåæ§ã®å±æ§ãæã€æ°ããªæ°çŸç ãåŒãèµ·ãããŠããããšãææ¡ããŸãã





















